Roche announced that its Phase III PEMPHIX study reveals the superiority of MabThera/Rituxan (rituximab) over mycophenolate mofetil in patients with pemphigus vulgaris (PV), a rare autoimmune disorder. The Swiss sponsor reported that 40% of the participating PV...